Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1826]

Predicting disease recurrence in patients with early triple-negative breast...

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

The emerging role of immunotherapy for the treatment of early and advanced...

Dr Rita Nanda - UChicago Medicine, Chicago, USA

The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

KRd consolidation in MM patients with a positive PET-CT after standard first...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

Complete remission after induction chemotherapy determines clinical efficacy of...

Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible...

Prof David Cairns - University of Leeds, Leeds, UK

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

More from ecancer